Approach towards an integrative drug treatment of Alzheimer's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 59, 2000, Pages 301-313

  Windisch, M ^a  

^a JSW Life Sciences GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CEREBROLYSIN; CHOLINESTERASE INHIBITOR; ESTROGEN; GLUCOSE TRANSPORTER; NEUROTROPHIN; NONSTEROID ANTIINFLAMMATORY AGENT; AMINO ACID; AMYLOID PRECURSOR PROTEIN; NOOTROPIC AGENT;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CHOLINERGIC NERVE CELL; CLINICAL TRIAL; COGNITION; DAILY LIFE ACTIVITY; DISEASE COURSE; HUMAN; MEMORY; META ANALYSIS; NERVE CELL DEGENERATION; PRIORITY JOURNAL; REVIEW; DRUG ANTAGONISM; METABOLISM; NEUROLOGY;

ALZHEIMER DISEASE; AMINO ACIDS; AMYLOID BETA-PROTEIN PRECURSOR; HUMANS; NEUROLOGY; NOOTROPIC AGENTS;

EID: 0033624432     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6781-6_32     Document Type: Review

References (98)

1. Aisen PS, Davis KL (1997) The search for disease-modifying treatment for Alzheimer's disease. Neurology 48(6): 35-41
2. Akai F, Hiruma S, Sato T, Iwamoto N, Fujimoto M, Ioku M, Hashimoto S (1992) Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain. Histol Histopathol 7: 213-221
3. Albeck DS, Hoffer BJ, Quissell D, Sanders LS, Zerbe G, Granholm ACE (1997) A non-invasive transport system for GDNF across the blood-brain barrier. Neuroreport 8: 2293-2298
4. Albrecht E, Hingel S, Crailsheim K, Windisch M (1993) The effects of Cerebrolysin on survival and sprouting of neurons from cerebral hemispheres and from the brainstem of chick embryos in vitro. Adv Biosci 87: 341-342
5. Amberla K, Nordberg A, Viitanen M, Winblad B (1993) Long-term treatment with tacrine (THA) in Alzheimer's disease-evaluation of neuropsychological data. Acta Neurol Scand 149: 55-57
6. Anand R, Gharabawi G (1996) Clinical development of ExelonTM (ENA-713): The Adena programme. J Drug Devel Clin Practice 8: 117-122
7. Anand R, Gharabawi G, Enz A (1996) Efficacy and safety results of the early phase studies with ExelonTM (ENA-713) in Alzheimer's disease: an overview. J Drug Devel Clin Practice 8: 109-116
8. Balson R, Gibson PR, Ames D, Bhathal PS (1995) Tacrine-induced hepatotoxicity. CNS Drugs 4: 168-181
9. Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S (1996) Double-blind, placebo-controlled study of Metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alzheimer Dis Assoc Disord 10: 124-131
10. Boado RJ (1995) Brain-derived peptides regulate the steady state levels and increase stability of the blood-brain barrier GLUT1 glucose transporter mRNA. Neurosci Lett 197: 179-182
11. Boado RJ (1996) Brain-derived peptides increase the expression of a blood-brain barrier GLUT1 glucose transporter reporter gene. Neurosci Lett 220: 53-56
12. Boado RJ, Wu D, Pardridge WM, Windisch M (1999) In vivo upregulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived peptides. Neurosci Res 34:217-224
13. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, Selk DE, Wolf V (1996) Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 277: 728-738
14. Breitner JCS (1996) Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol Aging 17: 789-794
15. Cordell B (1994) β-Amyloid formation as a potential therapeutic target for Alzheimer's disease. Annu Rev Pharmacol Toxicol 34: 69-89
16. Crook TH, Petrie W, Wells C, Massari D (1992) Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull 28: 61-66
17. Cummings BJ, Pike ChJ, Shankle R, Cotman CW (1996) β-Amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging 17/6: 921-933
18. Cummings J, Bieber F, Mas J, Orazem J, Gulanski B (1997) Metrifonate in Alzheimer's disease: results of a dose-finding study. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM (eds) Alzheimer's disease: biology, diagnosis and therapeutics. John Wiley, Chichester, pp 656-669
19. Cutler RN, Sramek J (1993) Tacrine in alzheimer's disease. N Engl J Med 808.
20. Davis LK, Thal JL, Gamzu ER, Davis SH, Woolson RF, Gracon ST, Drachman DA (1992) A double-blind placebo-controlled multicenter study of tacrine for Alzeheimer's disease. N Engl J Med 327: 1253-1259
21. Doody RS (1999) Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology 45 [Suppl 1]: 23-32
22. Ebert U, Kirch W (1998) Review - Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest 28: 944-949
23. Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, Schmitt FA, Sano M, Thomas RG, Ernesto C, Grundman M, Schafer K, Thal LJ (1997) A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: Overview and general results. Alzheimer Dis Assoc Disord 11: S1-S12
24. Flood JF, Cherkin A (1986) Scopolamine effects on memory retention in mice: A model of dementia. Behav Neural Biol 45: 169-184
25. Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66: 137-147
26. Francis-Turner L, Valouskova V (1996) Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study. Neurosci Lett 202: 1-4
27. Fratiglioni L, DeRonchi D, AgueroTorres H (1999) Worldwide prevalence and incidence of dementia. Drugs Aging 15: 365-375
28. Freeman SE, Dawson RM (1991) Tacrine: A pharmacological review. Prog Neurobiol 36: 257-277
29. Growdon JH, Corkin S, Huff FJ, Rosen TJ (1986) Piracetam combinded with lecithin in the treatment of Alzheimer's disease. Neurobiol Aging 7: 269-276
30. Gschanes A, Windisch M (1998) The influence of Cerebrolysin and E021 on spatial navigation of 24-month-old rats. J Neural Transm [Suppl 53]: 313-321
31. Gschanes A, Boado R, Sametz, Windisch M (2000) The drug Cerebrolysin and its peptide fraction E021 increase the abundance of the blood-brain barrier GLUT1 glucose transporter in brains of young and old rats. Histochem J (in press)
32. Hagg T, Fass-Holmes B, Vahlsing HL, Manthorpe M, Conner JM, Varon S (1989) Nerve growth factor (NGF) reverses axotomy-induced decreases in choline acetyl-transferase, NGF receptor and size of medial septum cholinergic neurons. Brain Res 505(1): 29-38
33. Hardy J (1997) Amyloid, the presenilins and Alzheimer's disease. TINS 20: 154-159
34. Hefti F (1999) Nerve growth factor treatment for Alzheimer's disease: The experience of the first attempt at intracerebral neurotrophic factor therapy. In: Hefti F (ed), Neurotrophic factors, Springer Berlin Heidelberg New York Tokyo, pp 175-187
35. Hefti F, Schneider LS (1991) Nerve growth factor and Alzheimer's disease. Clin Neuropharmacol 14/1: 62-76
36. Hellweg R, von Richthofen S, Anders D, Baethge C, Ropke S, Hartung HD, Gericke CA (1998) The time course of nerve growth factor content in different neuropsychiatric diseases - a unifying hypothesis - Review article. J Neural Transm 105: 871-903
37. Henderson, VW (1997a) Estrogen replacement therapy for the prevention and treatment of Alzheimer's disease. CNS Drugs 8: 343-351
38. Henderson VW (1997b) The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology 48: 27-35
39. Hock C, Heese K, Muller-Spahn F, Hulette C, Rosenberg C, Otten U (1998) Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease. Neurosci Lett 241: 151-154
40. Holford NHG, Peace K (1994) The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials. Eur J Clin Pharmacol 47: 17-23
41. Hull M, Fiebich BL, Schumann G, Lieb K, Bauer J (1999) Anti-inflammatory substances a new therapeutic option in Alzheimer's disease. Drug Discov Today 4: 275-282
42. Hutter-Paier B, Grygar E, Windisch M (1996) Death of cultured telencephalon neurons induced by glutamate is reduced by the peptide derivative Cerebrolysin. J Neural Transm 47: 267-273
43. Jette N, Cole MS, Fahnestock M (1994) NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. Mol Brain Res 25: 242-250
44. Jönhagen ME, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, Olson L, Seiger A, Shigeta M, Theodorsson E, Viitanen M, Winblad B, Wahlund LO (1998) Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 9: 246-257
45. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle DD, Metter E (1997) A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology 48: 1517-1521
46. Kisilevsky R (1996) Anti-amyloid drugs. Potential in the treatment of diseases associated with aging. Drugs Aging 8/2: 75-83
47. Kittner B, Rössner M, Rother M (1997) Clinical trials in dementia with propentofylline. Ann N Y Acad Sci 826: 307-316
48. Knapp JM, Gracon StI, Davis SCh, Solomon PR, Pendlebury W, Knopman DS (1994) Efficacy and safety of high-dose tacrine: A 30-week evaluation. Alzheimer Dis Assoc Disord 8/2: 22-31
49. Koopmans Summers W, Majovski LV, Marsh GM, Tachiki K, Kling A (1986) Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315: 1241-1245
50. Lansbury PT (1997) Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease, chemical biology 1: 260-267
51. Lindsay RM (1996) Therapeutic potential of the neurotrophins and neurotrophin-CNTF combinations in peripheral neuropathies and motor neuron diseases. Ciba Found Symp 196: 39-53
52. Lombardi VRM, Windisch M, Garcia M, Cacabelos R (1999) Effects of Cerebrolysin on in vitro primary microglial and astrocyte rat cell cultures. Methods Find Exp Clin Pharmacol 21: 331-338
53. MacKenzie IRA (1996) Antiinflammatory drugs in the treatment of Alzheimer's disease. J Rheumatol 23/5: 806-808
54. Masliah E, Armasolo F, Veinbergs I, Mallory M, Samuel W (1999) Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Behav 62: 239-245
55. Meier-Ruge W, Kolbe M, Sattler J (1991) Investigations of the cholinergic deficit hypothesis in the hippocampus of the aged rat brain with physostigmine and scopolamine. Arch Gerontol Geriatr 12: 239-251
56. Mor G, Nilsen J, Horvath T, Bechmann I, Brown S, GarciaSegura LM, Naftolin F (1999) Estrogen and microglia: A regulatory system that affects the brain. J Neurobiol 40: 484-496
57. Mufson EJ, Sobreviela T (1995) The NGF superfamily of neurotrophins: Potential treatment for Alzheimer's and Parkinson's disease. Behav Brain Sci 18: 63-65
58. Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H (1996) Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport 7: 1-4
59. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer amyloid precursor derivates stimulated by activation of muscarinic acetylcholine receptors. Science 258: 304-307
60. Nordberg A (1992) Biological markers and the cholinergic hypothesis in Alzheimer's disease. Acta Neurol Scand 139: 54-58
61. Pan WH, Banks WA, Kastin AJ (1998) Permeability of the blood-brain barrier to neurotrophins. Brain Res 788: 87-94
62. Pan YL, Anthony M, Clarkson TB (1999) Evidence for up-regulation of brain-derived neurotrophic factor mRNA by soy phytoestrogens in the frontal cortex of retired breeder female rats. Neurosci Lett 261: 17-20
63. Pepeu G, Pepeu IM, Amaducci L (1996) A Review of Phoshatidylserine pharmacological and clinical effects. Is Phosphatidylserine a drug for the ageing brain? Pharmacol Res 33/2: 73-80
64. Pollard BH, Rojas E, Arispe N (1994) β-Amyloid in Alzheimer's disease. Therapeutic implications. CNS Drugs 2/1: 1-6
65. Prentice N, Van Beck M, Dougall NJ, Moffoot PRA, O'Carroll RE, Goodwin GM, Ebmeier K (1996) A double-blind, placebo-controlled study of tacrine in patients with Alzheimer's disease using SPET. J Psychopharmacol 10/3: 175-181
66. Raffaele KC, Berardi A, Asthana S, Morris P, Haxby JV, Soncrant TT (1991) Effects of Long-therm continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type. Psychopharmacol Bull 27(3): 315-319
67. Robbins TW, McAlonan G, Muir JL, Everitt BJ (1997) Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease. Behav Brain Res 83: 15-23
68. Rogers SL, Friedhoff LT (1996) The efficacy and safety of Donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 7: 293-303
69. Rogers SL, Friedhoff LT (1998) Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 8: 67-75
70. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, Albala B, Baumel B, Booker G, Dexter J, Farmer M, Feighne JP, Ferris S, Gordon B, Gorman DG, Hanna G, Harrell LE, Hubbard R, Kennedy J, McCarthy J, Scharre DW, Schaerf F (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50: 136-145
71. Roßner S, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V (1998) The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog Neurobiol 56: 541-569
72. Rother M, Erkinjuntti T, Roessner M, Kittner B, Marcusson J, Karlsson I (1998) Propentofylline in the treatment of Alzheimer's disease and vascular dementia: A review of phase III trials. Dement Geriatr Cogn Disord 9 [Suppl 1]: 36-43
73. Rüther E, Ritter R, Apecechea M, Freytag S, Windisch M (1994) Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 27: 32-40
74. Saitoh T, Brugge K (1994) Is amyloid causally involved in pathophysiology of Alzheimer's disease? Neurobiol Aging 15/4: 461-462
75. Sano M, Ernesto Ch, Klauber MR, Schafer K, Woodbury P, Thomas R, Grundman M (1996) Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer Dis Assoc Disord 10: 132-140
76. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of Selegiline, Alpha-Tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 336: 1216-1222
77. Satou T, Imano M, Akai F, Hashimoto S, Itoh T, Fujimoto M (1993) Morphological observation of effects of Cerebrolysin on cultured neural cells. Adv Biosci 87: 195-196
78. Satou T, Itoh T, Fujimoto M, Hashimoto S (1994) Neurotrophic-like effects of FPF-1070 on cultured neurons from chick embryonic dorsal root ganglia. Jpn Pharmacol Ther 22/4: 205-212
79. Schwarz RD, Callahan MJ, Davis RE, Jaen JC, Tecle H (1997) Development of M-I subtype selective muscarinic agonists for Alzheimer's disease: Translation of in vitro selectivity into in vivo efficacy. Drug Dev Res 40: 133-143
80. Seiger A, Nordberg A, von Holst H, Bäckman L, Ebendal T, Alafuzoff I, Amberla K, Hartvig P, Herlitz A, Lilja A, Lundqvist H, Langström B, Meyerson B, Persson A, Viitanen M, Winblad B, Olson L (1993) Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. Behav Brain Res 57: 255-261
81. Shumaker SA, Reboussin BA, Espeland MA, Rapp SR, McBee WL, Dailey M, Bowen D, Terrell T, Jones BN (1998) The Women's Health Initiative Memory Study (WHIMS): A trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials 19: 604-621
82. Si Q, Nakamura Y, Schubert P, Rudolphi K, Kataoka K (1996) Adenosine and propentofylline inhibit the proliferation of cultured microglial cells. Exp Neurol 137: 345-349
83. Singer CA, McMillan PJ, Dobie DJ, Dorsa DM (1998) Effects of estrogen replacement oncholine acetyltransferase and trkA mRNA expression in the basal forebrain of aged rats. Brain Res 789: 343-346
84. Soto C (1999) Beta-amyloid disrupting drugs - potential in the treatment of Alzheimer's disease. CNS Drugs 12: 347-356
85. Stewart WF, Kawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer's disease and duration of NSAID use. J Neurol 48: 626-632
86. Svensson AL, Nordberg A (1998) Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells. Neuroreport 9: 1519-1522
87. Tanzi ER, Vaula G, Romano DM, Mortilla M, Huang LT, Tupler GR, Wasco W, Hyman BT (1992) Assessment of amyloid β-protein precursor gene mutations in a large set of familial and sporadic Alzheimer disease cases. Am J Hum Genet 51: 273-282
88. Terry RD (1996) The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 55/10: 1023-1025
89. Thomsen T, Bickel U, Fischer JP, Kewitz H (1990) Galanthamine hydrobromide in a long-term treatment of Alzheimer's disease. Dementia 1: 46-51
90. Valouskova V, Francis-Turner L (1998) Can Cerebrolysin influence chronic deterioration of spatial learning and memory? J Neural Transm [Suppl 53]: 343-349
91. Vassar R, Bennett BD, Babu Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, et al (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 28886: 735-741
92. Wagner SL, Munoz B (1999) Modulation of amyloid beta protein precursor processing as a means of retarding progression of Alzheimer's disease. J Clin Invest 104: 1329-1332
93. Weinstock M (1995) The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update. Neurodegeneration 4: 349-356
94. Windisch M, Paier B, Eggenreich U (1994) Neuronal growth factors and their role in degenerative brain diseases: A mini-review. Neurologia Croatica 43/2: 9-20
95. Windisch M, Gschanes A, Hutter-Paier B (1998) Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. J Neural Transm [Suppl 53]: 289-298
96. Windisch M, Gschanes A, Hutter-Paier B (1999) The usefulness of neurotrophic factors for tretament of Alzheimer's disease. Ann Psychiatry 7: 171-186
97. Yaffe K, Sawaya G, Lieberburg I, Grady D (1998) Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA 279: 688-695
98. Yamada K, Nitta A, Hasegawa T, Fuji K, Hiramatsu M, Kameyama T, Furukawa Y, Hayashi K, Nabeshimia T (1997) Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. Behav Brain Res 83: 117-122